Unstable Angina

AstraZeneca announced that it will close the STRENGTH CV outcomes trial of omega-3 carboxylic acids in patients with mixed dyslipidemia at high risk for CVD.

The risk for major adverse CV events after recent ACS could be predicted by baseline lipoprotein(a) and corrected LDL levels and their reductions with alirocumab, according to an analysis of the ODYSSEY Outcomes trial published in the Journal of the American College of Cardiology.

Women who were enrolled in clinical trials had a lower risk for major adverse CV events compared with men after non-ST segment elevation ACS, according to a sex-specific analysis published in the Journal of the American College of Cardiology.

Even a small perfusion deficit substantially amplifies risk for major adverse cardiovascular events among adults with diabetes vs. those without, according to findings published in Diabetes Care.

Adding clinical judgment and ECG results to the European Society of Cardiology high-sensitivity cardiac troponin measurement algorithm for predicting major adverse CV events enhanced success at ruling out 30-day events, researchers reported.